File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/0387-7604(95)00038-D
- Scopus: eid_2-s2.0-0029113503
- PMID: 7503385
- WOS: WOS:A1995RR68100003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Open label trial with vigabatrin in children with intractable epilepsy
Title | Open label trial with vigabatrin in children with intractable epilepsy |
---|---|
Authors | |
Keywords | Children Intractable epilepsy Vigabatrin |
Issue Date | 1995 |
Publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/braindev |
Citation | Brain And Development, 1995, v. 17 n. 4, p. 249-252 How to Cite? |
Abstract | Thirty children (20 males, 10 females) with intractable epilepsy received vigabatrin (VGB) as an open label basis to preexisting antiepileptic drugs. The seizure types consisted of generalized tonic clonic seizure [10], complex partial seizure [8], myoclonic seizure [7], and mixed type with simple partial seizure, complex partial seizure and/or generalized seizure [5]. The cause of the epilepsy was cryptogenic in 16 and symptomatic in 12. The current dosage regime of anticonvulsants were maintained during the trial period. VGB at 40-80 mg/kg/day were titrated according to the clinical response for a period of 2-24 months. The result of treatment was categorized as 'responders' with 13 (43%) having 50-75% reduction of seizure frequency; and 'non-responders' which consisted of 17 children. There was no relationship between outcome of VBG add-on therapy and the sex, age of onset, type of seizure, type of epileptic syndrome, etiology, associated neurological abnormality, mental retardation or abnormal brain CT/MRI findings. |
Persistent Identifier | http://hdl.handle.net/10722/143591 |
ISSN | 2023 Impact Factor: 1.4 2023 SCImago Journal Rankings: 0.498 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, V | en_HK |
dc.date.accessioned | 2011-12-12T03:52:09Z | - |
dc.date.available | 2011-12-12T03:52:09Z | - |
dc.date.issued | 1995 | en_HK |
dc.identifier.citation | Brain And Development, 1995, v. 17 n. 4, p. 249-252 | en_HK |
dc.identifier.issn | 0387-7604 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/143591 | - |
dc.description.abstract | Thirty children (20 males, 10 females) with intractable epilepsy received vigabatrin (VGB) as an open label basis to preexisting antiepileptic drugs. The seizure types consisted of generalized tonic clonic seizure [10], complex partial seizure [8], myoclonic seizure [7], and mixed type with simple partial seizure, complex partial seizure and/or generalized seizure [5]. The cause of the epilepsy was cryptogenic in 16 and symptomatic in 12. The current dosage regime of anticonvulsants were maintained during the trial period. VGB at 40-80 mg/kg/day were titrated according to the clinical response for a period of 2-24 months. The result of treatment was categorized as 'responders' with 13 (43%) having 50-75% reduction of seizure frequency; and 'non-responders' which consisted of 17 children. There was no relationship between outcome of VBG add-on therapy and the sex, age of onset, type of seizure, type of epileptic syndrome, etiology, associated neurological abnormality, mental retardation or abnormal brain CT/MRI findings. | en_HK |
dc.language | eng | en_US |
dc.publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/braindev | en_HK |
dc.relation.ispartof | Brain and Development | en_HK |
dc.subject | Children | en_HK |
dc.subject | Intractable epilepsy | en_HK |
dc.subject | Vigabatrin | en_HK |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Age of Onset | en_US |
dc.subject.mesh | Anticonvulsants/adverse effects/*therapeutic use | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Child, Preschool | en_US |
dc.subject.mesh | Drug Resistance | en_US |
dc.subject.mesh | Epilepsy/complications/*drug therapy/psychology | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Magnetic Resonance Imaging | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Tomography, X-Ray Computed | en_US |
dc.subject.mesh | Treatment Outcome | en_US |
dc.subject.mesh | Vigabatrin | en_US |
dc.subject.mesh | gamma-Aminobutyric Acid/adverse effects/*analogs & derivatives/therapeutic | en_US |
dc.title | Open label trial with vigabatrin in children with intractable epilepsy | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Wong, V:vcnwong@hku.hk | en_HK |
dc.identifier.authority | Wong, V=rp00334 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/0387-7604(95)00038-D | en_HK |
dc.identifier.pmid | 7503385 | en_HK |
dc.identifier.scopus | eid_2-s2.0-0029113503 | en_HK |
dc.identifier.volume | 17 | en_HK |
dc.identifier.issue | 4 | en_HK |
dc.identifier.spage | 249 | en_HK |
dc.identifier.epage | 252 | en_HK |
dc.identifier.isi | WOS:A1995RR68100003 | - |
dc.publisher.place | Netherlands | en_HK |
dc.identifier.scopusauthorid | Wong, V=7202525632 | en_HK |
dc.identifier.issnl | 0387-7604 | - |